
The success of targeted therapies for cancer is zzso strong zzso evidence has resulted in the approval of several new agents for cancer zzso The type I zzso growth factor zzso zzso appeared to be one of these promising new zzso zzso population and zzso data have all pointed toward this zzso as an important regulator of tumor cell zzso Although early results from clinical trials that targeted the zzso showed some evidence of response, larger zzso phase III trials have not shown clear clinical benefit of targeting this zzso in combination with conventional zzso These disappointing results have resulted in the zzso of several zzso zzso However, the conduct of these trials has brought to the forefront several important factors that need to be considered in the conduct of future clinical zzso The need to develop zzso a clearer understanding of insulin zzso function, and defining rational combination regimens all require further zzso In this commentary, the current state of zzso zzso in cancer therapy is zzso 

